Home
Diseases
Uterine Cancer

Uterine Cancer

Disease

Disease Profile

Uterine cancer is cancer arising in the uterus, most commonly endometrial carcinoma. It is one of the most common gynecologic malignancies and incidence has been increasing in many populations.

Category: Malignant neoplasms
Prevalence: Estimated 69,120 new uterine corpus cancer cases in the U.S. in 2025

ICD Codes

Related News

Multiple Studies Link Accelerated Biological Aging to Rising Early-Onset Cancer in Younger Generations

Jun 29, 2026

Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.

Racial Disparities Persist Across Cancer Incidence and Clinical Trial Outcomes

Jun 02, 2026

Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.

FDA Grants Fast Track to SIM0505 for Platinum-Resistant Ovarian Cancer

Apr 08, 2026

The FDA granted fast track designation to SIM0505, a CDH6-targeting antibody-drug conjugate, for platinum-resistant ovarian cancer based on preclinical and early clinical data. A phase 1 trial is currently evaluating the drug in advanced solid tumors, with initial data expected at the 2026 ASCO conference. The company plans to begin dose optimization studies in ovarian cancer patients in Q2 2026.

FDA Removes Black Box Warning from Menopausal Hormone Therapy Products

Feb 13, 2026

The FDA has approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had been in place since 2003.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07581288	Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression	NOT_YET_RECRUITING
NCT07542704	A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies	NOT_YET_RECRUITING	PHASE1
NCT06904365	Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women	ACTIVE_NOT_RECRUITING
NCT05743517	Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)	RECRUITING	NA
NCT05579366	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	RECRUITING	PHASE1/PHASE2
NCT05559879	Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma	RECRUITING	PHASE1/PHASE2
NCT03762733	Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies	ENROLLING_BY_INVITATION